Shikonin inhibits MRSA biofilm formation to alleviate periprosthetic joint infection
Frontiers in Pharmacology · 06.03.2026 · 17
DOI: 10.3389/fphar.2026.1739888 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.03.2026. Verfasst von Shangyi Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First College of Clinical Medical Science and Yichang Central People's Hospital, China Three Gorges University, Yichan…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To alleviate periprosthetic joint infection (PJI) with methicillin-resistant Staphylococcus aureus (MRSA), shikonin (SKN) had been used to intervene the biofilm formation of MRSA in vivo and in vitro , which provides theoretical support and practical foundation for SKN as a novel drug against drug-resistant bacterial infection.
Methods
The rat model of periprosthetic joint infection was established, utilizing techniques such as scanning electron microscopy and pathology test to evaluate the MRSA inhibitory of bacterial load and biofilm formation effects of SKN. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) experiments were conducted to assess the antibacterial activity of SKN. The crystal violet staining method was employed to evaluate the effects of SKN on MRSA biofilm formation and eradication. Transcriptomic and amino acid metabolomics analyses were used to investigate the mechanism of SKN inhibition in MRSA biofilm formation. Total thiol detection was used to assess the impact of SKN on the intracellular cysteine levels in MRSA. Finally, MIC and crystal violet staining were used to evaluate the antibacterial effects and biofilm eradication efficacy of SKN against clinical MRSA strains.
Results
In vivo experimental results demonstrated that high doses of SKN significantly reduced the biofilm formation in MRSA PJI in rats, improved local inflammatory responses, and promoted tissue repair. Observations using scanning electron microscopy confirmed that SKN effectively inhibited the formation of biofilms on implant surface. MIC experiments revealed that the lowest inhibitory concentration of SKN was 70 μM, indicating significant antibacterial activity, although no direct bactericidal effects were observed. Results of crystal violet staining showed that SKN could significantly inhibit biofilm formation of MRSA at sublethal concentrations and exhibited efficacy of biofilm removal. Transcriptomic and acid amino metabolomic analyses prompted that the inhibition of MRSA biofilm formation by SKN might be related to regulate the cysteine metabolism in MRSA. Total thiol detection was used to validate the omics findings in vitro . Finally, SKN intervention in MRSA clinical strains showed that the SKN could inhibit MRSA clinical strains and remove biofilm.
Conclusion
SKN inhibits MRSA by suppressing biofilm formation, effectively alleviating periprosthetic joint infection by MRSA, and the mechanism of SKN antibacterial activity may be related to regulate the cysteine metabolism in MRSA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, The First College of Clinical Medical Science and Yichang Central People's Hospital, China Three Gorges University, Yichang, China.
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy and College of Basic Medical Sciences, China Three Gorges University, Yichang, China.
- Yichang Key Laboratory of Infection and Inflammation, College of Basic Medical Sciences, China Three Gorges University, Yichang, China.
Zitieren
APA
Liu, S., Zhang, H., Zheng, X., Mou, X., Wu, Z., Zou, L., Shou, K., & Liu, X. (2026). Shikonin inhibits MRSA biofilm formation to alleviate periprosthetic joint infection. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1739888
Vancouver
Liu S, Zhang H, Zheng X, Mou X, Wu Z, Zou L, et al. Shikonin inhibits MRSA biofilm formation to alleviate periprosthetic joint infection. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1739888
BibTeX
@article{Liu2026,
author = {Liu, Shangyi and Zhang, Haoran and Zheng, Xi and Mou, Xiaoqin and Wu, Zhongbao and Zou, Lili and Shou, Kangquan and Liu, Xiaowen},
title = {Shikonin inhibits MRSA biofilm formation to alleviate periprosthetic joint infection},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1739888}
}
EUVIMED